Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04619680 · ClinicalTrials.gov registry record · Phase 4
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
A Phase 4 study of Interstitial Lung Disease and Pulmonary Fibrosis, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 121
- Enrollment target
- 7
- Study locations
NCT04619680 is a Phase 4 study of Interstitial Lung Disease and Pulmonary Fibrosis that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 121 participants, below the 563-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (79% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT04619680, a Phase 4 study of Interstitial Lung Disease and Pulmonary Fibrosis, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 121 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of lung disease in patients who have been diagnosed with COVID-19, and have ongoing lung injury more than 30 days out from their diagnosis. Required one of the following after diagnosis with SARS-CoV-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as CPAP or BIPAP, or mechanical ventilation or a history of desaturation below 90%.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nintedanib
Study Locations (7)
New York
- Mount Sinai Beth Israel - New York
- Icahn School of Medicine at Mount Sinai - New York
Texas
- Baylor University Medical Center Dallas - Dallas
- Baylor College of Medicine - Houston
Georgia
- Emory Healthcare Network - Atlanta
Maryland
- The Johns Hopkins Hospital - Baltimore
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2024-03-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04619680
The ClinicalTrials.gov registry entry for NCT04619680 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 563-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (79% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04619680 reports 7 study locations spanning 5 distinct geographic areas - top geographies include New York, Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT04619680 about?
NCT04619680 is a clinical study titled "The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19". This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of lung disease in patients who have been diagnosed with COVID-19, and have o...
What is the current status of trial NCT04619680?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 121 participants. The study started on 2020-11-18. Estimated completion is 2024-03-02.
What conditions does trial NCT04619680 study?
This clinical trial studies the following conditions: Interstitial Lung Disease, Pulmonary Fibrosis, Respiratory Disease.
What interventions are being tested in trial NCT04619680?
The interventions under investigation include: Placebo (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT04619680?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04619680 being conducted?
This trial has 7 study locations across Georgia, Maryland, New York, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
RECRUITING · Phase 3
-
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
RECRUITING
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.